Skip to main content
Clinical Trials/NCT02270281
NCT02270281CompletedPhase 4

Dexmedetomidine Improve Microcirculatory Alterations in Initial Resuscitated Septic Shock Patients

Southeast University, China1 site in 1 country44 target enrollmentStarted: December 2014Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
44
Locations
1
Primary Endpoint
Perfused vascular density

Study Overview

Brief Summary

Dexmedetomidine was found might be beneficial to sepsis. Dexmedetomidine were found to improve microcirculation in sepsis animal studies and non-sepsis patients. However, the effect of dexmedetomidine on microcirculation in septic shock patients is unknown.

Detailed Description

Septic shock is characterized by significant decline in vascular response and relative hypovolemia. Fluids and exogenous catecholamines are mainstay. However, even after initial resuscitation, microcirculatory dysfunctions still exist, and represent a direct physiologic link to organ failure and death. Therefore, therapeutic strategies aiming at improving microcirculation are performed.

Dexmedetomidine was found might be beneficial to sepsis. Dexmedetomidine were found to improve microcirculation in sepsis animal studies and non-sepsis patients. However, the effect of dexmedetomidine on microcirculation in septic shock patients is unknown.

Based on the hypothesis that dexmedetomidine might improve microcirculation in initial resuscitated septic shock patients, the study was to investigate the effects of dexmedetomidine on microcirculation in early septic shock patients despite initial resuscitation. Meanwhile, to observe the possible mechanism of the effect, the correlation between dexmedetomidine dose and microcirculatory parameters as well as catecholamine level were performed.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Dexmedetomidine

Other

Before dexmedetomidine infusion

Intervention: Dexmedetomidine 0.7 Mcg/kg/h (Drug)

Outcomes

Primary Outcomes

Perfused vascular density

Time Frame: One hour

Perfused vascular density was calculated by multiplying vessel density by the proportion of perfused vessels

Secondary Outcomes

  • Total vascular density(One hour)
  • Microcirculatory flow index(One hour)

Investigators

Sponsor
Southeast University, China
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jingyuan,Xu

MD

Southeast University, China

Study Sites (1)

Loading locations...

Similar Trials